Thalidomide alone or in combination: results in refractory patients


https://doi.org/10.4081/hmr.v1i11.350
Vol. 1 No. 11: Thalidomide in the treatment of multiple myeloma, Sydney, 10 April 2005
Published: June 5, 2009
Abstract Views: 202
PDF: 335
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Thalidomide was first marketed in the 1950s for the treatment of pregnancy-related morning sickness and later as a sedative, but was withdrawn because of serious adverse events in pregnant women including teratogenicity and dysmelia.1 Interest in the drug resurfaced in the 1990s because of its antiangiogenic and immunomodulatory effects.2 Recently thalidomide has been used to treat multiple myeloma (MM) either alone or in combination with other therapies. This review summarizes study results of thalidomide treatment in patients who have not benefited from conventional therapy.

Supporting Agencies


San Miguel, J. F. (2009). Thalidomide alone or in combination: results in refractory patients. Hematology Meeting Reports (formerly Haematologica Reports), 1(11). https://doi.org/10.4081/hmr.v1i11.350
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC